BIO Share Price

Open 28.20 Change Price %
High 28.35 1 Day 0.10 0.35
Low 28.10 1 Week -0.08 -0.28
Close 28.30 1 Month 1.05 3.85
Volume 5878 1 Year 11.94 72.98
52 Week High 28.60
52 Week Low 15.66
BIO Important Levels
Resistance 2 28.53
Resistance 1 28.44
Pivot 28.25
Support 1 28.16
Support 2 28.07
ETR Germany Most Active Stocks
CBK 9.48 2.16%
CBK 9.48 2.16%
DBK 15.04 0.94%
DBK 15.04 0.94%
EOAN 8.96 0.67%
EOAN 8.96 0.67%
DTE 16.62 -0.24%
DTE 16.62 -0.24%
DTE 16.62 -0.24%
DTE 16.62 -0.24%
More..
ETR Germany Top Gainers Stocks
S9H 0.16 45.45%
5M71 39.00 13.70%
WAC 21.11 11.22%
WAC 21.11 11.22%
WAC 21.11 11.22%
CFC 0.60 11.11%
CFC 0.60 11.11%
YSN 98.50 10.67%
ZSB 0.12 9.09%
USX1 20.21 7.50%
More..
ETR Germany Top Losers Stocks
MPI 0.25 -98.98%
MPI 0.25 -98.98%
APL 2.60 -34.18%
APL 2.60 -34.18%
APL 2.60 -34.18%
TLI 0.15 -16.67%
TLI 0.15 -16.67%
IS8 11.09 -11.63%
FAC 0.24 -11.11%
FAC 0.24 -11.11%
More..

Biotest AG (ETR: BIO)

BIO Technical Analysis 5
As on 26th Jun 2017 BIO Share Price closed @ 28.30 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 19.83 & Strong Buy for SHORT-TERM with Stoploss of 27.62 we also expect STOCK to react on Following IMPORTANT LEVELS.
BIO Target for June
1st Target up-side 27.7
2nd Target up-side 28.02
3rd Target up-side 28.34
1st Target down-side 26.8
2nd Target down-side 26.48
3rd Target down-side 26.16
BIO Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.biotest.de
BIO Address
BIO
Landsteinerstrasse 5
Dreieich, 63303
Germany
Phone: 49 6103 801 4406
Fax: 49 6103 801 347
BIO Latest News
Interactive Technical Analysis Chart Biotest AG ( BIO ETR Germany )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Biotest AG
BIO Business Profile
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological medicinal products worldwide. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin for haemophilia A acute therapy and prophylaxis; Haemonine for haemophilia B acute therapy and prophylaxis; Bivigam for primary immune deficiency; Cytotect for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in newborns; Hepatect CP for hepatitis B re-infection prophylaxis; Intratect for primary immune deficiency and secondary antibody deficiency syndromes, as well as autoimmune diseases; Nabi-HB for prophylaxis of hepatitis B virus infection; Varitect CP for zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. The company also provides Albiomin for volume depletion; Biseko for the deficiency of volume and serum proteins; Cofact for the deficiency of clotting factors; Humanalbumin for volume depletion; and Pentaglobin for the treatment of severe bacterial infections. In addition, its products under development include Indatuximab Ravtansine (BT-062) for multiple myeloma and solid tumors; BT-063 for the treatment of systemic lupus erythematosus; BT-094 (Cytotect 70) for the treatment of congenital cytomegalovirus infections; Civacir for the treatment of hepatitis C infection; Tregalizumab (BT-061) for the treatment of rheumatoid arthritis and psoriasis; Fibrinogen for the deficiency of fibrinogen; and IgM concentrate for severe bacterial infections. Biotest Aktiengesellschaft has a collaboration agreement with AbbVie for the development of monoclonal antibody BT-061. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany.